PTC Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good morning, everyone. Thanks for joining us for another session, at the forty-fourth JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On at the podium, we have, the CEO of PTCC Therapeutics, Matt Klein. I'll now pass the mic to, Matt, for a short presentation followed by a live audience Q&A.
Thank you, Brian, and thank you everyone for joining us this morning.
Last year, I stood on this stage and talked about how 2025 was going to be a year of focus and execution for PTC, positioning us for future success.
We set a number of objectives for the year, including gaining the first approvals for Sufiance for the treatment of children and adults of PKU, ensuring a strong start to the Saffiance global launch, continue to drive revenue and effectively manage expenses as we continue to move the company towards cash flow breakeven, and advance our innovative early-stage
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
